BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3 Article Swipe

View

Li Ma , Jianwei Wang , Yang Yang , Jun Lü , Jing Ling , Xinran Chu , Zi-Mu Zhang , Yanfang Tao , Xiaolu Li , Yuanyuan Tian , Zhiheng Li , Yongping Zhang , Xu Sang , Lihui Lu , Xiaomei Wan , Kunlong Zhang , Yanling Chen , Juanjuan Yu , Ran Zhuo , Shuiyan Wu , Ji‐An Pan , Xiuxia Zhou , Yixin Hu , Shaoyan Hu ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.6084/m9.figshare.23988963

B-cell acute lymphoblastic leukemia (B-ALL) is the most prevalent malignant tumor affecting children. While the majority of B-ALL patients (90%) experience successful recovery, early relapse cases of B-ALL continue to exhibit high mortality rates. MZ1, a novel inhibitor of Bromodomains and extra-terminal (BET) proteins, has demonstrated potent antitumor activity against hematological malignancies. The objective of this study was to examine the role and therapeutic potential of MZ1 in the treatment of B-ALL. In order to ascertain the fundamental mechanism of MZ1, a sequence of in vitro assays was conducted on B-ALL cell lines, encompassing Cell Counting Kit 8 (CCK8) assay, Propidium iodide (PI) staining, and Annexin V/PI staining. Western blotting and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to examine protein and mRNA expression levels. Transcriptomic RNA sequencing (RNA-seq) was utilized to screen the target genes of MZ1, and lentiviral transfection was employed to establish stably-expressing/knockdown cell lines. MZ1 has been observed to induce the degradation of Bromodomain Containing 4 (BRD4), Bromodomain Containing 3 (BRD3), and Bromodomain Containing 2 (BRD2) in B-ALL cell strains, leading to inhibited cell growth and induction of cell apoptosis and cycle arrest in vitro. These findings suggest that MZ1 exhibits cytotoxic effects on two distinct molecular subtypes of B-ALL, namely 697 (TCF3/PBX1) and RS4;11 (MLL-AF4) B-ALL cell lines. Additionally, RNA-sequencing analysis revealed that MZ1 significantly downregulated the expression of Cyclin D3 (CCND3) gene in B-ALL cell lines, which in turn promoted cell apoptosis, blocked cell cycle, and caused cell proliferation inhibition. Our results suggest that MZ1 has potential anti-B-ALL effects and might be a novel therapeutic target.

Related Topics

Acute Lymphoblastic Leukemia

Concepts

Lymphoblastic Leukemia Medicine Cancer research Pharmacology Leukemia Chemistry Internal medicine

Metadata

Type: dataset
Language: en
Landing Page: https://doi.org/10.6084/m9.figshare.23988963
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4394537410

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4394537410

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.6084/m9.figshare.23988963

Digital Object Identifier
Title: BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3

Work title
Type: dataset

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-01-01

Full publication date if available
Authors: Li Ma, Jianwei Wang, Yang Yang, Jun Lü, Jing Ling, Xinran Chu, Zi-Mu Zhang, Yanfang Tao, Xiaolu Li, Yuanyuan Tian, Zhiheng Li, Yongping Zhang, Xu Sang, Lihui Lu, Xiaomei Wan, Kunlong Zhang, Yanling Chen, Juanjuan Yu, Ran Zhuo, Shuiyan Wu, Ji‐An Pan, Xiuxia Zhou, Yixin Hu, Shaoyan Hu

List of authors in order
Landing page: https://doi.org/10.6084/m9.figshare.23988963

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.6084/m9.figshare.23988963

Direct OA link when available
Concepts: Lymphoblastic Leukemia, Medicine, Cancer research, Pharmacology, Leukemia, Chemistry, Internal medicine

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4394537410
doi	https://doi.org/10.6084/m9.figshare.23988963
ids.doi	https://doi.org/10.6084/m9.figshare.23988963
ids.openalex	https://openalex.org/W4394537410
fwci
type	dataset
title	BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T12534
topics[0].field.id	https://openalex.org/fields/13
topics[0].field.display_name	Biochemistry, Genetics and Molecular Biology
topics[0].score	0.9994999766349792
topics[0].domain.id	https://openalex.org/domains/1
topics[0].domain.display_name	Life Sciences
topics[0].subfield.id	https://openalex.org/subfields/1312
topics[0].subfield.display_name	Molecular Biology
topics[0].display_name	Protein Degradation and Inhibitors
topics[1].id	https://openalex.org/T11491
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9908999800682068
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	CAR-T cell therapy research
topics[2].id	https://openalex.org/T10649
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9800000190734863
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2720
topics[2].subfield.display_name	Hematology
topics[2].display_name	Multiple Myeloma Research and Treatments
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2909962599
concepts[0].level	3
concepts[0].score	0.6418361663818359
concepts[0].wikidata	https://www.wikidata.org/wiki/Q180664
concepts[0].display_name	Lymphoblastic Leukemia
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.4215601980686188
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C502942594
concepts[2].level	1
concepts[2].score	0.4198913872241974
concepts[2].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[2].display_name	Cancer research
concepts[3].id	https://openalex.org/C98274493
concepts[3].level	1
concepts[3].score	0.40124645829200745
concepts[3].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[3].display_name	Pharmacology
concepts[4].id	https://openalex.org/C2778461978
concepts[4].level	2
concepts[4].score	0.3617979884147644
concepts[4].wikidata	https://www.wikidata.org/wiki/Q29496
concepts[4].display_name	Leukemia
concepts[5].id	https://openalex.org/C185592680
concepts[5].level	0
concepts[5].score	0.3488474488258362
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[5].display_name	Chemistry
concepts[6].id	https://openalex.org/C126322002
concepts[6].level	1
concepts[6].score	0.2630002498626709
concepts[6].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[6].display_name	Internal medicine
keywords[0].id	https://openalex.org/keywords/lymphoblastic-leukemia
keywords[0].score	0.6418361663818359
keywords[0].display_name	Lymphoblastic Leukemia
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.4215601980686188
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/cancer-research
keywords[2].score	0.4198913872241974
keywords[2].display_name	Cancer research
keywords[3].id	https://openalex.org/keywords/pharmacology
keywords[3].score	0.40124645829200745
keywords[3].display_name	Pharmacology
keywords[4].id	https://openalex.org/keywords/leukemia
keywords[4].score	0.3617979884147644
keywords[4].display_name	Leukemia
keywords[5].id	https://openalex.org/keywords/chemistry
keywords[5].score	0.3488474488258362
keywords[5].display_name	Chemistry
keywords[6].id	https://openalex.org/keywords/internal-medicine
keywords[6].score	0.2630002498626709
keywords[6].display_name	Internal medicine
language	en
locations[0].id	doi:10.6084/m9.figshare.23988963
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version
locations[0].raw_type	dataset
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	False
locations[0].is_published
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.6084/m9.figshare.23988963
indexed_in	datacite
authorships[0].author.id	https://openalex.org/A5113170362
authorships[0].author.orcid
authorships[0].author.display_name	Li Ma
authorships[0].author_position	first
authorships[0].raw_author_name	Li Ma
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5100424784
authorships[1].author.orcid	https://orcid.org/0000-0002-1116-4559
authorships[1].author.display_name	Jianwei Wang
authorships[1].author_position	middle
authorships[1].raw_author_name	Jianwei Wang
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5100397512
authorships[2].author.orcid	https://orcid.org/0000-0002-1269-2804
authorships[2].author.display_name	Yang Yang
authorships[2].author_position	middle
authorships[2].raw_author_name	Yang Yang
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5100617401
authorships[3].author.orcid	https://orcid.org/0000-0002-7343-9706
authorships[3].author.display_name	Jun Lü
authorships[3].author_position	middle
authorships[3].raw_author_name	Jun Lu
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5088489274
authorships[4].author.orcid	https://orcid.org/0000-0003-3929-140X
authorships[4].author.display_name	Jing Ling
authorships[4].author_position	middle
authorships[4].raw_author_name	Jing Ling
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5018628237
authorships[5].author.orcid
authorships[5].author.display_name	Xinran Chu
authorships[5].author_position	middle
authorships[5].raw_author_name	Xinran Chu
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5080278932
authorships[6].author.orcid	https://orcid.org/0000-0002-7791-4252
authorships[6].author.display_name	Zi-Mu Zhang
authorships[6].author_position	middle
authorships[6].raw_author_name	Zimu Zhang
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5113927002
authorships[7].author.orcid
authorships[7].author.display_name	Yanfang Tao
authorships[7].author_position	middle
authorships[7].raw_author_name	Yanfang Tao
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5100382147
authorships[8].author.orcid	https://orcid.org/0000-0002-9474-2931
authorships[8].author.display_name	Xiaolu Li
authorships[8].author_position	middle
authorships[8].raw_author_name	Xiaolu Li
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5101698600
authorships[9].author.orcid	https://orcid.org/0000-0003-1739-3579
authorships[9].author.display_name	Yuanyuan Tian
authorships[9].author_position	middle
authorships[9].raw_author_name	Yuanyuan Tian
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5108054267
authorships[10].author.orcid	https://orcid.org/0000-0002-2977-2624
authorships[10].author.display_name	Zhiheng Li
authorships[10].author_position	middle
authorships[10].raw_author_name	Zhiheng Li
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5100714499
authorships[11].author.orcid	https://orcid.org/0000-0001-5090-9173
authorships[11].author.display_name	Yongping Zhang
authorships[11].author_position	middle
authorships[11].raw_author_name	Yongping Zhang
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5049982506
authorships[12].author.orcid	https://orcid.org/0000-0001-7689-9778
authorships[12].author.display_name	Xu Sang
authorships[12].author_position	middle
authorships[12].raw_author_name	Xu Sang
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5089668716
authorships[13].author.orcid
authorships[13].author.display_name	Lihui Lu
authorships[13].author_position	middle
authorships[13].raw_author_name	Lihui Lu
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5082695523
authorships[14].author.orcid
authorships[14].author.display_name	Xiaomei Wan
authorships[14].author_position	middle
authorships[14].raw_author_name	Xiaomei Wan
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5026400577
authorships[15].author.orcid
authorships[15].author.display_name	Kunlong Zhang
authorships[15].author_position	middle
authorships[15].raw_author_name	Kunlong Zhang
authorships[15].is_corresponding	False
authorships[16].author.id	https://openalex.org/A5100629226
authorships[16].author.orcid	https://orcid.org/0000-0002-6975-915X
authorships[16].author.display_name	Yanling Chen
authorships[16].author_position	middle
authorships[16].raw_author_name	Yanling Chen
authorships[16].is_corresponding	False
authorships[17].author.id	https://openalex.org/A5102846631
authorships[17].author.orcid
authorships[17].author.display_name	Juanjuan Yu
authorships[17].author_position	middle
authorships[17].raw_author_name	Juanjuan Yu
authorships[17].is_corresponding	False
authorships[18].author.id	https://openalex.org/A5101515541
authorships[18].author.orcid	https://orcid.org/0000-0003-3180-643X
authorships[18].author.display_name	Ran Zhuo
authorships[18].author_position	middle
authorships[18].raw_author_name	Ran Zhuo
authorships[18].is_corresponding	False
authorships[19].author.id	https://openalex.org/A5071059730
authorships[19].author.orcid	https://orcid.org/0000-0002-8963-5082
authorships[19].author.display_name	Shuiyan Wu
authorships[19].author_position	middle
authorships[19].raw_author_name	Shuiyan Wu
authorships[19].is_corresponding	False
authorships[20].author.id	https://openalex.org/A5022611054
authorships[20].author.orcid
authorships[20].author.display_name	Ji‐An Pan
authorships[20].author_position	middle
authorships[20].raw_author_name	Jian Pan
authorships[20].is_corresponding	False
authorships[21].author.id	https://openalex.org/A5021707712
authorships[21].author.orcid	https://orcid.org/0000-0003-1562-103X
authorships[21].author.display_name	Xiuxia Zhou
authorships[21].author_position	middle
authorships[21].raw_author_name	Xiuxia Zhou
authorships[21].is_corresponding	False
authorships[22].author.id	https://openalex.org/A5011415232
authorships[22].author.orcid	https://orcid.org/0000-0001-9392-8016
authorships[22].author.display_name	Yixin Hu
authorships[22].author_position	middle
authorships[22].raw_author_name	Yixin Hu
authorships[22].is_corresponding	False
authorships[23].author.id	https://openalex.org/A5070166399
authorships[23].author.orcid	https://orcid.org/0000-0002-3386-6957
authorships[23].author.display_name	Shaoyan Hu
authorships[23].author_position	last
authorships[23].raw_author_name	Shaoyan Hu
authorships[23].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.6084/m9.figshare.23988963
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T06:51:31.235846
primary_topic.id	https://openalex.org/T12534
primary_topic.field.id	https://openalex.org/fields/13
primary_topic.field.display_name	Biochemistry, Genetics and Molecular Biology
primary_topic.score	0.9994999766349792
primary_topic.domain.id	https://openalex.org/domains/1
primary_topic.domain.display_name	Life Sciences
primary_topic.subfield.id	https://openalex.org/subfields/1312
primary_topic.subfield.display_name	Molecular Biology
primary_topic.display_name	Protein Degradation and Inhibitors
related_works	https://openalex.org/W4387497383, https://openalex.org/W2948807893, https://openalex.org/W2778153218, https://openalex.org/W2748952813, https://openalex.org/W1531601525, https://openalex.org/W4391375266, https://openalex.org/W2078814861, https://openalex.org/W2527526854, https://openalex.org/W1976181487, https://openalex.org/W1986764834
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.6084/m9.figshare.23988963
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version
best_oa_location.raw_type	dataset
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	False
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.6084/m9.figshare.23988963
primary_location.id	doi:10.6084/m9.figshare.23988963
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version
primary_location.raw_type	dataset
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	False
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.6084/m9.figshare.23988963
publication_date	2023-01-01
publication_year	2023
referenced_works_count	0
abstract_inverted_index.2	169
abstract_inverted_index.3	164
abstract_inverted_index.4	160
abstract_inverted_index.8	97
abstract_inverted_index.a	35, 81, 259
abstract_inverted_index.D3	226
abstract_inverted_index.In	72
abstract_inverted_index.be	258
abstract_inverted_index.in	67, 84, 171, 188, 229, 234
abstract_inverted_index.is	5
abstract_inverted_index.of	16, 26, 38, 54, 65, 70, 79, 83, 137, 157, 182, 203, 224
abstract_inverted_index.on	89, 198
abstract_inverted_index.to	29, 58, 74, 119, 132, 144, 153, 176
abstract_inverted_index.697	206
abstract_inverted_index.Kit	96
abstract_inverted_index.MZ1	66, 149, 194, 219, 251
abstract_inverted_index.Our	247
abstract_inverted_index.RNA	127
abstract_inverted_index.The	52
abstract_inverted_index.and	40, 62, 104, 110, 122, 139, 166, 180, 185, 208, 242, 256
abstract_inverted_index.has	44, 150, 252
abstract_inverted_index.the	6, 14, 60, 68, 76, 134, 155, 222
abstract_inverted_index.two	199
abstract_inverted_index.was	57, 87, 130, 142
abstract_inverted_index.(PI)	102
abstract_inverted_index.Cell	94
abstract_inverted_index.MZ1,	34, 80, 138
abstract_inverted_index.V/PI	106
abstract_inverted_index.been	151
abstract_inverted_index.cell	91, 147, 173, 178, 183, 212, 231, 237, 240, 244
abstract_inverted_index.gene	228
abstract_inverted_index.high	31
abstract_inverted_index.mRNA	123
abstract_inverted_index.most	7
abstract_inverted_index.role	61
abstract_inverted_index.that	193, 218, 250
abstract_inverted_index.this	55
abstract_inverted_index.turn	235
abstract_inverted_index.were	117
abstract_inverted_index.(90%)	19
abstract_inverted_index.(BET)	42
abstract_inverted_index.B-ALL	17, 27, 90, 172, 211, 230
abstract_inverted_index.These	190
abstract_inverted_index.While	13
abstract_inverted_index.acute	1
abstract_inverted_index.cases	25
abstract_inverted_index.chain	114
abstract_inverted_index.cycle	186
abstract_inverted_index.early	23
abstract_inverted_index.genes	136
abstract_inverted_index.might	257
abstract_inverted_index.novel	36, 260
abstract_inverted_index.order	73
abstract_inverted_index.study	56
abstract_inverted_index.tumor	10
abstract_inverted_index.vitro	85
abstract_inverted_index.which	233
abstract_inverted_index.(BRD2)	170
abstract_inverted_index.(CCK8)	98
abstract_inverted_index.B-ALL,	204
abstract_inverted_index.B-ALL.	71
abstract_inverted_index.B-cell	0
abstract_inverted_index.Cyclin	225
abstract_inverted_index.RS4;11	209
abstract_inverted_index.arrest	187
abstract_inverted_index.assay,	99
abstract_inverted_index.assays	86
abstract_inverted_index.caused	243
abstract_inverted_index.cycle,	241
abstract_inverted_index.growth	179
abstract_inverted_index.induce	154
abstract_inverted_index.iodide	101
abstract_inverted_index.lines,	92, 232
abstract_inverted_index.lines.	148, 213
abstract_inverted_index.namely	205
abstract_inverted_index.potent	46
abstract_inverted_index.rates.	33
abstract_inverted_index.screen	133
abstract_inverted_index.target	135
abstract_inverted_index.vitro.	189
abstract_inverted_index.(B-ALL)	4
abstract_inverted_index.(BRD3),	165
abstract_inverted_index.(BRD4),	161
abstract_inverted_index.(CCND3)	227
abstract_inverted_index.Annexin	105
abstract_inverted_index.Western	108
abstract_inverted_index.against	49
abstract_inverted_index.blocked	239
abstract_inverted_index.effects	197, 255
abstract_inverted_index.examine	59, 120
abstract_inverted_index.exhibit	30
abstract_inverted_index.leading	175
abstract_inverted_index.levels.	125
abstract_inverted_index.protein	121
abstract_inverted_index.relapse	24
abstract_inverted_index.results	248
abstract_inverted_index.suggest	192, 249
abstract_inverted_index.target.	262
abstract_inverted_index.Counting	95
abstract_inverted_index.activity	48
abstract_inverted_index.analysis	216
abstract_inverted_index.blotting	109
abstract_inverted_index.continue	28
abstract_inverted_index.distinct	200
abstract_inverted_index.employed	118, 143
abstract_inverted_index.exhibits	195
abstract_inverted_index.findings	191
abstract_inverted_index.leukemia	3
abstract_inverted_index.majority	15
abstract_inverted_index.observed	152
abstract_inverted_index.patients	18
abstract_inverted_index.promoted	236
abstract_inverted_index.reaction	115
abstract_inverted_index.revealed	217
abstract_inverted_index.sequence	82
abstract_inverted_index.strains,	174
abstract_inverted_index.subtypes	202
abstract_inverted_index.utilized	131
abstract_inverted_index.(MLL-AF4)	210
abstract_inverted_index.(RNA-seq)	129
abstract_inverted_index.(qRT-PCR)	116
abstract_inverted_index.Propidium	100
abstract_inverted_index.affecting	11
abstract_inverted_index.antitumor	47
abstract_inverted_index.apoptosis	184
abstract_inverted_index.ascertain	75
abstract_inverted_index.children.	12
abstract_inverted_index.conducted	88
abstract_inverted_index.cytotoxic	196
abstract_inverted_index.establish	145
abstract_inverted_index.induction	181
abstract_inverted_index.inhibited	177
abstract_inverted_index.inhibitor	37
abstract_inverted_index.malignant	9
abstract_inverted_index.mechanism	78
abstract_inverted_index.molecular	201
abstract_inverted_index.mortality	32
abstract_inverted_index.objective	53
abstract_inverted_index.potential	64, 253
abstract_inverted_index.prevalent	8
abstract_inverted_index.proteins,	43
abstract_inverted_index.real-time	112
abstract_inverted_index.recovery,	22
abstract_inverted_index.staining,	103
abstract_inverted_index.staining.	107
abstract_inverted_index.treatment	69
abstract_inverted_index.Containing	159, 163, 168
abstract_inverted_index.anti-B-ALL	254
abstract_inverted_index.apoptosis,	238
abstract_inverted_index.experience	20
abstract_inverted_index.expression	124, 223
abstract_inverted_index.lentiviral	140
abstract_inverted_index.polymerase	113
abstract_inverted_index.sequencing	128
abstract_inverted_index.successful	21
abstract_inverted_index.(TCF3/PBX1)	207
abstract_inverted_index.Bromodomain	158, 162, 167
abstract_inverted_index.degradation	156
abstract_inverted_index.fundamental	77
abstract_inverted_index.inhibition.	246
abstract_inverted_index.therapeutic	63, 261
abstract_inverted_index.Bromodomains	39
abstract_inverted_index.demonstrated	45
abstract_inverted_index.encompassing	93
abstract_inverted_index.quantitative	111
abstract_inverted_index.transfection	141
abstract_inverted_index.Additionally,	214
abstract_inverted_index.downregulated	221
abstract_inverted_index.hematological	50
abstract_inverted_index.lymphoblastic	2
abstract_inverted_index.malignancies.	51
abstract_inverted_index.proliferation	245
abstract_inverted_index.significantly	220
abstract_inverted_index.RNA-sequencing	215
abstract_inverted_index.Transcriptomic	126
abstract_inverted_index.extra-terminal	41
abstract_inverted_index.stably-expressing/knockdown	146
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	24
citation_normalized_percentile